{"title":"克唑替尼致暴发性肝衰竭的成功治疗:1例报告及文献复习。","authors":"Kyle Kreitman, Satheesh P Nair, Jiten P Kothadia","doi":"10.1155/2020/8247960","DOIUrl":null,"url":null,"abstract":"<p><p>Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. Crizotinib-induced hepatotoxicity is a rare event. We report a case of a 46-year-old female with a history of metastatic lung cancer who presented with acute liver failure after being on crizotinib for two months. The medication was discontinued, and she was treated with N-acetylcysteine for seven days. Her liver function tests returned to normal limits after 26 days after admission. The precise mechanism and risk factors of crizotinib-induced hepatotoxicity remain unknown. Physicians should be aware of the potentially lethal side effect caused by crizotinib.</p>","PeriodicalId":30295,"journal":{"name":"Case Reports in Hepatology","volume":"2020 ","pages":"8247960"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8247960","citationCount":"9","resultStr":"{\"title\":\"Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature.\",\"authors\":\"Kyle Kreitman, Satheesh P Nair, Jiten P Kothadia\",\"doi\":\"10.1155/2020/8247960\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. Crizotinib-induced hepatotoxicity is a rare event. We report a case of a 46-year-old female with a history of metastatic lung cancer who presented with acute liver failure after being on crizotinib for two months. The medication was discontinued, and she was treated with N-acetylcysteine for seven days. Her liver function tests returned to normal limits after 26 days after admission. The precise mechanism and risk factors of crizotinib-induced hepatotoxicity remain unknown. Physicians should be aware of the potentially lethal side effect caused by crizotinib.</p>\",\"PeriodicalId\":30295,\"journal\":{\"name\":\"Case Reports in Hepatology\",\"volume\":\"2020 \",\"pages\":\"8247960\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/8247960\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/8247960\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/8247960","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature.
Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. Crizotinib-induced hepatotoxicity is a rare event. We report a case of a 46-year-old female with a history of metastatic lung cancer who presented with acute liver failure after being on crizotinib for two months. The medication was discontinued, and she was treated with N-acetylcysteine for seven days. Her liver function tests returned to normal limits after 26 days after admission. The precise mechanism and risk factors of crizotinib-induced hepatotoxicity remain unknown. Physicians should be aware of the potentially lethal side effect caused by crizotinib.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
